MedTrace Logo

Effect of High Velocity/Hyperoxic Breathing Therapy on Blood Lactate Decline

NCT05984186 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-10-08

Study results available
· View outcomes & findings →

Summary

The study will evaluate the impact of high velocity therapy (HVT) on reduction of work of breathing (as implied by breath frequency) and enhanced blood lactate decline during recovery from a Wingate-type Exercise test. The study will include four study segments, corresponding to four different therapy settings.

Conditions

  • Dyspnea
  • Lactic Acidosis
  • Muscle
  • Breathlessness
  • Exercise
  • Recovery

Interventions

DEVICE

High Velocity Therapy

FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM

Sponsors & Collaborators

  • Auburn University

    collaborator OTHER

  • Vapotherm, Inc.

    lead INDUSTRY

Principal Investigators

  • Bruce Gladden · Auburn University

  • Michael Roberts · Auburn University

  • Max Michael · Auburn University

  • Nina Stute · Auburn University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2023-07-31
Completion
2023-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05984186 on ClinicalTrials.gov